PureTech Health: Putting The “Z” In IP Commercialisation
This article was originally published in Start Up
IP commercialization may be all the rage for company creation in the UK, but it remains comparatively unknown in the US. Daphne Zohar of Boston-based PureTech Health talks to START-UP about her firm’s approach to creating and developing life science businesses.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.